Hypochlorite-modified albumin colocalizes with RAGE in the artery wall and promotes MCP-1 expression via the RAGE-Erk1/2 MAP-kinase pathway

FASEB Journal

Volumn 21, Issue 4, 2007, Pages 1145-1152

  Marsche, Gunther ^a   Semlitsch, Michaela ^a   Hammer, Astrid ^a   Frank, Sasa ^a   Weigle, Bernd ^c   Demling, Nina ^c   Schmidt, Kurt ^d   Windischhofer, Werner ^b   Waeg, Georg ^e   Sattler, Wolfgang ^a   Malle, Ernst ^a  

^a MEDICAL UNIVERSITY OF GRAZ   (Austria)

^b ST ANNA CHILDREN S HOSPITAL   (Austria)

^c DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^d UNIVERSITY OF GRAZ   (Austria)

^e Institute of Molecular Biosciences   (Austria)

Author keywords

AOPP; Hypochlorous acid; Inflammation; Myeloperoxidase

Indexed keywords

ADVANCED GLYCATION END PRODUCT RECEPTOR; ALBUMIN; HYDROGEN PEROXIDE; HYPOCHLORITE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1;

ARTERY ENDOTHELIUM; ARTERY WALL; ARTICLE; ATHEROMA; BINDING AFFINITY; CELL ACTIVATION; CONTROLLED STUDY; HUMAN; HUMAN CELL; HUMAN TISSUE; IMMUNOFLUORESCENCE; IMMUNOHISTOCHEMISTRY; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; PROTEIN PROTEIN INTERACTION;

ALBUMINS; ANTIGENS, NEOPLASM; ARTERIES; CELL LINE; CHEMOKINE CCL2; GENE EXPRESSION REGULATION; HUMANS; HYPOCHLOROUS ACID; INFLAMMATION; MAP KINASE SIGNALING SYSTEM; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; MITOGEN-ACTIVATED PROTEIN KINASES; PEROXIDASE; SIGNAL TRANSDUCTION;

EID: 33947632950     PISSN: 08926638     EISSN: None     Source Type: Journal    
DOI: 10.1096/fj.06-7439com     Document Type: Article

References (40)

1. Wautier, J. L., and Schmidt, A. M. (2004) Protein glycation. A firm link to endothelial cell dysfunction. Circ. Res. 95, 233-238
2. Witko-Sarsat, V., Friedlander, M., Capeillere-Blandin, C., Nguyen-Khoa, T., Nguyen, A. T., Zingraff, J., Jungers, P., and Descamps-Latscha, B. (1996) Advanced oxidation protein products as a novel marker of oxidative stress in uremia. Kidney. Int. 49, 1304-1313
3. Witko-Sarsat, V., Friedlander, M., Nguyen, Khoa. T., Capeillere-Blandin, C., Nguyen, A.T., Canteloup, S., Dayer, J. M., Jungers, P., Drueke, T., and Descamps-Latscha, B. (1998) Advanced oxidation protein products as novel mediators of inflammation and monocyte activation in chronic renal failure. J. Immunol. 161, 2524-2532
4. Capeillere-Blandin, C., Gausson, V., Descamps-Latscha, B., and Witko-Sarsat, V. (2004) Biochemical and spectrophotometric significance of advanced oxidized protein products. Biochim. Biophys. Acta. 1689, 91-102
5. Tiruppathi, C., Naqvi, T., Wu, Y., Vogel, S. M., Minshall, R. D., and Malik, A. B. (2004) Albumin mediates the transcytosis of myeloperoxidase by means of caveolae in endothelial cells. Proc. Natl. Acad. Sci. U. S. A. 101, 7699-7704
6. Liu, S. X., Hou, F. F., Guo, Z. J., Nagai, R., Zhang, W. R., Liu, Z. Q., Zhou, Z. M., Zhou, M., Xie, D., and Wang, G. B., et al. (2006) Advanced oxidation protein products accelerate atherosclerosis through promoting oxidative stress and inflammation. Arterioscler. Thromb. Vasc. Biol. 26, 1156-1162
7. Witko-Sarsat, V., Gausson, V., Nguyen, A. T., Touam, M., Drueke, T., Santangelo, F., and Descamps-Latscha, B. (2003) AOPP-induced activation of human neutrophil and monocyte oxidative metabolism: a potential target for N-acetylcysteine treatment in dialysis patients. Kidney. Int. 64, 82-91
8. Rodriguez-Ayala, E., Anderstam, B., Suliman, M. E., Seeberger, A., Heimburger, O., Lindholm, B., and Stenvinkel, P. (2005) Enhanced RAGE-mediated NF-κB stimulation in inflamed hemodialysis patients. Atherosclerosis 180, 333-340
9. Zheng, L., Nukuna, B., Brennan, M.L., Sun, M., Goormastic, M., Settle, M., Schmitt, D., Fu, X., Thomson, L., and Fox, P. L. et al. (2004) Apolipoprotein A-I is a selective target for myeloperoxidase-catalyzed oxidation and functional impairment in subjects with cardiovascular disease. J. Clin. Invest. 114, 529 -541
10. Malle, E., Waeg, G., Schreiber, R., Gröne, E., Sattler, W., and Gröne, H. J. (2000) Immunohistochemical evidence for the myeloperoxidase/H2O2/halide system in human atherosclerotic lesions: colocalization of myeloperoxidase and hypochlorite-modified proteins. Eur. J. Biochem. 267, 4495-4503
11. Malle, E., Marsche, G., Panzenboeck, U., and Sattler, W. (2006) Modification of low-density lipoprotein by myeloperoxidase-derived oxidants and reagent hypochlorous acid. Arch. Biochem. Biophys. 445, 245-255
12. Cipollone, F., Iezzi, A., Fazia, M., Zucchelli, M., Pini, B., Cuccurullo, C., De Cesare, D., De Blasis, G., Muraro, R., and Bei, R. et al. (2003) The receptor RAGE as a progression factor amplifying arachidonate-dependent inflammatory and proteolytic response in human atherosclerotic plaques: role of glycemic control. Circulation 108, 1070-1077
13. Schmidt, A. M., Yan, S. D., Yan, S. F., and Stern, D. M. (2001) The multiligand receptor RAGE as a progression factor amplifying immune and inflammatory responses. J. Clin. Invest. 108, 949-955
14. Hazell, L. J., Arnold, L., Flowers, D., Waeg, G., Malle, E., and Stocker, R. (1996) Presence of hypochlorite-modified proteins in human atherosclerotic lesions. J. Clin. Invest. 97, 1535-1544
15. Malle, E., Wäg, G., Thiery, J., Sattler, W., and Gröne, H. J. (2001) Hypochlorite-modified (lipo)proteins are present in rabbit lesions in response to dietary cholesterol. Biochem. Biophys. Res. Commun. 289, 894-900
16. Marsche, G., Hammer, A., Oskolkova, O., Kozarsky, K. F., Sattler, W., and Malle, E. (2002) Hypochlorite-modified high density lipoprotein, a high affinity ligand to scavenger receptor class B, type I, impairs high density lipoprotein-dependent selective lipid uptake and reverse cholesterol transport. J. Biol. Chem. 277, 32172-32179
17. Marsche, G., Heller, R., Fauler, G., Kovacevic, A., Nuszkowski, A., Graier, W., Sattler, W., and Malle, E. (2004) 2-chlorohexadecanal derived from hypochlorite-modified high-density lipoprotein-associated plasmalogen is a natural inhibitor of endothelial nitric oxide biosynthesis. Arterioscler. Thromb. Vasc. Biol. 24, 2302-2306
18. Malle, E., Hazell, L., Stocker, R., Sattler, W., Esterbauer, H., and Waeg, G. (1995) Immunologic detection and measurement of hypochlorite-modified LDL with specific monoclonal antibodies. Arterioscler. Thromb. Vasc. Biol. 15, 982-989
19. Takata, K., Horiuchi, S., Araki, N., Shiga, M., Saitoh, M., and Morino, Y. (1988) Endocytic uptake of nonenzymatically glycosylated proteins is mediated by a scavenger receptor for aldehyde-modified proteins. J. Biol. Chem. 263, 14819-14825
20. Demling, N., Ehrhardt, C., Kasper, M., Laue, M., Knels, L., and Rieber, E. P. (2006) Promotion of cell adherence and spreading: a novel function of RAGE, the highly selective differentiation marker of human alveolar epithelial type I cells. Cell Tissue Res. 323, 475-488
21. Hsieh, H. L., Schafer, B. W., Weigle, B., and Heizmann, C. W. (2004) S100 protein translocation in response to extracellular S100 is mediated by receptor for advanced glycation endproducts in human endothelial cells. Biochem. Biophys. Res. Commun. 316, 949-959
22. Srikrishna, S., Huttunen, H. J., Johansson, L., Weigle, B., Yamaguchi, Y., Rauvala, H., and Freeze, H. H. (2002) N-Glycans on the receptor for advanced glycation end products influence amphoterin binding and neurite outgrowth. J. Neurochem. 80, 998-1008
23. Marsche, G., Levak-Frank, S., Quehenberger, O., Heller, R., Sattler, W., and Malle, E. (2001) Identification of the human analog of SR-BI and LOX-1 as receptors for hypochlorite-modified high-density lipoprotein on human umbilical venous endothelial cells. FASEB J. 15, 1095-1097
24. Strauss, J. G., Hayn, M., Zechner, R., Levak-Frank, S., and Frank, S. (2003) Fatty acids liberated from high-density lipoprotein phospholipids by endothelial-derived lipase are incorporated into lipids in HepG2 cells. Biochem. J. 371, 981-988
25. Valencia, J. V., Stephen, C. W., Douglas, Q., Geesje, H. K., DeGroot, J., TeKoppele, J. M., and Hughes, T. E. (2004) Advanced glycation end product ligands for the receptor for advanced glycation end products: biochemical characterization and formation kinetics. Anal. Biochem. 324, 68-78
26. Lander, H. M., Tauras, J. M., Ogiste, J. S., Hori, O., Moss, R. A., and Schmidt, A. M. (1997) Activation of the receptor for advanced glycation end products triggers a p21(ras)-dependent mitogen-activated protein kinase pathway regulated by oxidant stress. J. Biol. Chem. 272, 17810-17814
27. Lau, D., Mollnau, H., Eiserich, J. P., Freeman, B. A., Daiber, A., Gehling, U. M., Brummer, J., Rudolph, V., Munzel, T., Heitzer, T., et al. (2005) Myeloperoxidase mediates neutrophil activation by association with CD11b/CD18 integrins. Proc. Natl. Acad. Sci. U. S. A. 102, 431-436
28. Peters, W. and Charo, I. F. (2001) Involvement of chemokine receptor 2 and its ligand, monocyte chemoattractant protein-1, in the development of atherosclerosis: lessons from knockout mice. Curr. Opin. Lipidol. 12, 175-180
29. Naka, Y., Bucciarelli, L. G., Wendt, T., Lee, L. K., Rong, L. L., Ramasamy, R., Yan, S. F., and Schmidt, A. M. (2004) RAGE axis: Animal models and novel insights into the vascular complications of diabetes. Arterioscler. Thromb. Vasc. Biol. 24, 1342-1349
30. ε-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274, 31740-31749
31. Anderson, M. M., Requena, J. R., Crowley, J. R., Thorpe, S. R., Heinecke, J. W. (1999) The myeloperoxidase system of human phagocytes generates N?-(carboxymethyl)lysine on proteins: a mechanism for producing advanced glycation end products at sites of inflammation. J. Clin. Invest. 104, 103-113
32. Ritthaler, U., Deng, Y., Zhang, Y., Greten, J., Abel, M., Sido, B., Allenberg, J., Otto, G., Roth, H., Bierhaus, A., et al. (1995) Expression of receptors for advanced glycation end products in peripheral occlusive vascular disease. Am. J. Pathol. 146, 688-694
33. Park, L., Raman, K.G., Lee, K. J., Lu, Y., Ferran, L. J. Jr., Chow, W.S., Stern. D., and Schmidt, A. M. (1998) Suppression of accelerated diabetic atherosclerosis by the soluble receptor for advanced glycation endproducts. Nat. Med. 4, 1025-1031
34. Yan, S. F., Ramasamy, R., Naka, Y., and Schmidt, A. M. (2003) Glycation, inflammation, and RAGE: a scaffold for the macrovascular complications of diabetes and beyond. Circ. Res. 93, 1159-1169
35. Yoshimura, T., Yuhki, N., Moore, S. K., Appella, E., Lerman, M. I., and Leonard, E. J. (1989) Human monocyte chemoattractant protein-1 (MCP-1): full-length cDNA cloning, expression in mitogen-stimulated blood mononuclear leukocytes, and sequence similarity to mouse competence gene JE. FEBS Lett. 244, 487-493
36. Gosling, J., Slaymaker, S., Gu, L., Tseng, S., Zlot, C. H., Young, S. G., Rollins, B. J., and Charo, I. F. (1999) MCP-1 deficiency reduces susceptibility to atherosclerosis in mice that overexpress human apolipoprotein B. J. Clin. Invest. 103, 773-778
37. Bräsen, J. H., Hakkinen, T., Malle, E., Beisiegel, U., and Yla-Herttuala, S. (2003) Patterns of oxidized epitopes, but not NF-κB expression, change during atherogenesis in WHHL rabbits. Atherosclerosis 166, 13-21
38. Chen, Y. L., Chang, Y. J., and Jiang, M. J. (1999) Monocyte chemotactic protein-1 gene and protein expression in atherogenesis of hypercholesterolemic rabbits. Atherosclerosis 143, 115-123
39. Murakami, S., Kondo, Y., Sakurai, T., Kitajima, H., and Nagate, T. (2002) Taurine suppresses development of atherosclerosis in Watanabe heritable hyperlipidemic (WHHL) rabbits. Atherosclerosis. 163, 79-87
40. Liu, Y. and Quinn, M. R. (2002) Chemokine production by rat alveolar macrophages is inhibited by taurine chloramine. Immunol. Lett. 80, 27-32